project id: TCGA-THCA; case submitter id: TCGA-ET-A25O; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.6; rna integrity number: 7.5; spectrophotometer method: UV Spec; age at index: 35; days to birth: -12924; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1974; age at diagnosis: 12924; ajcc pathologic m: MX; ajcc pathologic n: N1a; ajcc pathologic stage: Stage I; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1986.0; icd 10 code: C73; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Thyroid gland; synchronous malignancy: No; tissue or organ of origin: Thyroid gland; tumor grade: Not Reported; year of diagnosis: 2009; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 560; days to sample procurement: 0; initial weight: 90.0; portion submitter id: TCGA-ET-A25O-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 94.0;